Pasqualon Tobias, Pruessmeyer Jessica, Jankowski Vera, Babendreyer Aaron, Groth Esther, Schumacher Julian, Koenen Andrea, Weidenfeld Sarah, Schwarz Nicole, Denecke Bernd, Jahr Holger, Dreymueller Daniela, Jankowski Joachim, Ludwig Andreas
Institute of Pharmacology and Toxicology, RWTH Aachen University, Aachen, Germany.
Institute of Molecular Cardiovascular Research, RWTH Aachen University, Aachen, Germany.
Oncotarget. 2015 Oct 13;6(31):31295-312. doi: 10.18632/oncotarget.5174.
Syndecan-1 is a surface expressed heparan sulphate proteoglycan, which is upregulated by several tumor types and involved in tumor cell migration and metastasis. Syndecan-1 is shed from the cell surface and the remaining transmembrane fragment undergoes intramembrane proteolysis by γ-secretase. We here show that this generates a cytoplasmic C-terminal fragment (cCTF). In epithelial lung tumor A549 cells the endogenously produced cCTF accumulated when its proteasomal degradation was blocked with bortezomib and this accumulation was prevented by γ-secretase inhibition. Overexpression of the cCTF suppressed migration and invasion of A549 cells. This inhibitory effect was only seen when endogenous Syndecan-1 was present, but not in Syndecan-1 deficient cells. Further, overexpression of Syndecan-1 cCTF increased the basal activation of Src kinase, focal adhesion kinase (FAK) and Rho GTPase. This was associated with increased adhesion to fibronectin and collagen G and an increased recruitment of paxillin to focal adhesions. Moreover, lung tumor formation of A549 cells in mice was reduced by overexpression of Syndecan-1 cCTF. Finally, delivery of a synthetic peptide corresponding to the Syndecan-1 cCTF suppressed A549 cell migration and increased basal phosphorylation of Src and FAK. Our data indicate that the Syndecan-1 cCTF antagonizes Syndecan-1 dependent tumor cell migration in vitro and in vivo by dysregulating proadhesive signaling pathways and suggest that the cCTF can be used as an inhibitory peptide.
Syndecan-1是一种表面表达的硫酸乙酰肝素蛋白聚糖,在多种肿瘤类型中上调,并参与肿瘤细胞的迁移和转移。Syndecan-1从细胞表面脱落,剩余的跨膜片段通过γ-分泌酶进行膜内蛋白水解。我们在此表明,这会产生一个细胞质C末端片段(cCTF)。在肺上皮肿瘤A549细胞中,当用硼替佐米阻断其蛋白酶体降解时,内源性产生的cCTF会积累,而γ-分泌酶抑制可阻止这种积累。cCTF过表达抑制了A549细胞的迁移和侵袭。这种抑制作用仅在内源性Syndecan-1存在时可见,而在Syndecan-1缺陷细胞中则未观察到。此外,Syndecan-1 cCTF过表达增加了Src激酶、粘着斑激酶(FAK)和Rho GTP酶的基础激活。这与对纤连蛋白和胶原蛋白G的粘附增加以及桩蛋白向粘着斑的募集增加有关。此外,Syndecan-1 cCTF过表达减少了A549细胞在小鼠体内的肿瘤形成。最后,递送与Syndecan-1 cCTF对应的合成肽可抑制A549细胞迁移,并增加Src和FAK的基础磷酸化。我们的数据表明,Syndecan-1 cCTF通过失调促粘附信号通路在体外和体内拮抗Syndecan-1依赖性肿瘤细胞迁移,并表明cCTF可作为一种抑制性肽。